Takeda Initiates Phase 3 Trial of Motesanib in Japan and Additional Asian Countries-- Takeda obtains the exclusive worldwide rights to develop, manufacture and commercialize motesanib --

OSAKA, Japan, July 26, 2012 – Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) and Millennium: The Takeda Oncology Company, a subsidiary of Takeda (“Millennium”), today announces that Takeda Bio Development Center Limited has ini..

Original Article: Takeda Initiates Phase 3 Trial of Motesanib in Japan and Additional Asian Countries-- Takeda obtains the exclusive worldwide rights to develop, manufacture and commercialize motesanib --

More From BioPortfolio on "Takeda Initiates Phase 3 Trial of Motesanib in Japan and Additional Asian Countries-- Takeda obtains the exclusive worldwide rights to develop, manufacture and commercialize motesanib --"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications